Literature DB >> 34623592

Influence of GSTP1 rs1695 polymorphism on survival in male patients' amyotrophic lateral sclerosis: a genetic association study in Brazilian population.

Rodrigo da Silva Santos1, Angela Adamski da Silva Reis2, Jéssica Barletto de Sousa Barros3, Kamilla de Faria Santos3, Dhiogo da Cruz Pereira Bento3,4, Leandro do Prado Assunção3.   

Abstract

BACKGROUND: Glutathione S-transferase Pi (GSTP1) enzyme has a major antioxidant effect on the central nervous system (CNS), where it acts against oxidative damage, an established risk factor for amyotrophic lateral sclerosis (ALS). Hence, the purpose of this study was to evaluate a possible relationship between GSTP1 rs1695 polymorphism and the survival rate of male ALS patients, which is the gender more affected by the disease. METHODS AND
RESULTS: A case-control study was performed with 56 male ALS patients and 70 healthy male individuals from Midwestern Brazil, which were age-adjusted. GSTP1 rs1695 polymorphism molecular analysis was carried out with restriction fragment length polymorphism. The relationship between ALS patients and GSTP1 rs1695 polymorphism was analyzed using cumulative survival rate as the major outcome, where differences in survival were evaluated through the log-rank test. Our results revealed that mutant genotype (G/G) did not influence the cumulative survival rate of male ALS patients regarding the age of diagnosis (p = 0.5) and time from symptom to diagnosis (p = 0.3). On the other hand, mutant carriers exhibited a significant survival of fewer than 25 months compared to A/A and A/G genotypes that survive more than 100 months (p = 7-E10) in comparison with symptom onset to outcome (p = 0.00006).
CONCLUSIONS: In summary, our findings revealed that mutant genotype carriers' male patients had a reduced lifetime, which probably may be resulted from oxidative stress exposure in CNS.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Amyotrophic lateral sclerosis (ALS); GSTP1 rs1695 SNP; Genetic polymorphism; Oxidative damage; Survival rate

Mesh:

Substances:

Year:  2021        PMID: 34623592     DOI: 10.1007/s11033-021-06724-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  12 in total

1.  A study of glutathione S-transferase pi expression in central nervous system of subjects with amyotrophic lateral sclerosis using RNA extraction from formalin-fixed, paraffin-embedded material.

Authors:  Ewa Usarek; Beata Gajewska; Beata Kaźmierczak; Magdalena Kuźma; Dorota Dziewulska; Anna Barańczyk-Kuźma
Journal:  Neurochem Res       Date:  2005-08       Impact factor: 3.996

Review 2.  Histamine beyond its effects on allergy: Potential therapeutic benefits for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Authors:  Cinzia Volonté; Savina Apolloni; Mario Sabatelli
Journal:  Pharmacol Ther       Date:  2019-06-22       Impact factor: 12.310

Review 3.  Amyotrophic lateral sclerosis: a hormonal condition?

Authors:  Helene Blasco; Anne-Marie Guennoc; Charlotte Veyrat-Durebex; Paul H Gordon; Christian R Andres; William Camu; Philippe Corcia
Journal:  Amyotroph Lateral Scler       Date:  2012-08-08

4.  GSTP1 Polymorphisms and their Association with Glutathione Transferase and Peroxidase Activities in Patients with Motor Neuron Disease.

Authors:  Beata Gajewska; Beata Kaźmierczak; Magdalena Kuźma-Kozakiewicz; Zygmunt Jamrozik; Anna Barańczyk-Kuźma
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

5.  Differences in glutathione S-transferase pi expression in transgenic mice with symptoms of neurodegeneration.

Authors:  Beata Kaźmierczak; Magdalena Kuźma-Kozakiewicz; Ewa Usarek; Anna Barańczyk-Kuźma
Journal:  Acta Biochim Pol       Date:  2011-11-30       Impact factor: 2.149

Review 6.  Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

Authors:  Emanuele D'Amico; Pam Factor-Litvak; Regina M Santella; Hiroshi Mitsumoto
Journal:  Free Radic Biol Med       Date:  2013-06-21       Impact factor: 7.376

7.  Modification of the association between lead exposure and amyotrophic lateral sclerosis by iron and oxidative stress related gene polymorphisms.

Authors:  Ki-Do Eum; Ryan M Seals; Kathryn M Taylor; Matthew Grespin; David M Umbach; Howard Hu; Dale P Sandler; Freya Kamel; Marc G Weisskopf
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-10-08       Impact factor: 4.092

8.  Activity and expression of glutathione S-transferase pi in patients with amyotrophic lateral sclerosis.

Authors:  Magdalena Kuźma; Zygmunt Jamrozik; Anna Barańczyk-Kuźma
Journal:  Clin Chim Acta       Date:  2005-08-18       Impact factor: 3.786

9.  STrengthening the REporting of Genetic Association Studies (STREGA)--an extension of the STROBE statement.

Authors:  Julian Little; Julian P T Higgins; John P A Ioannidis; David Moher; France Gagnon; Erik von Elm; Muin J Khoury; Barbara Cohen; George Davey-Smith; Jeremy Grimshaw; Paul Scheet; Marta Gwinn; Robin E Williamson; Guang Yong Zou; Kim Hutchings; Candice Y Johnson; Valerie Tait; Miriam Wiens; Jean Golding; Cornelia van Duijn; John McLaughlin; Andrew Paterson; George Wells; Isabel Fortier; Matthew Freedman; Maja Zecevic; Richard King; Claire Infante-Rivard; Alex Stewart; Nick Birkett
Journal:  Genet Epidemiol       Date:  2009-11       Impact factor: 2.135

Review 10.  The increasing importance of environmental conditions in amyotrophic lateral sclerosis.

Authors:  Javier Riancho; Pilar Bosque-Varela; Sara Perez-Pereda; Mónica Povedano; Adolfo López de Munaín; Ana Santurtun
Journal:  Int J Biometeorol       Date:  2018-04-30       Impact factor: 3.787

View more
  1 in total

1.  Genetic factors for survival in amyotrophic lateral sclerosis: an integrated approach combining a systematic review, pairwise and network meta-analysis.

Authors:  Wei-Ming Su; Xiao-Jing Gu; Qing-Qing Duan; Zheng Jiang; Xia Gao; Hui-Fang Shang; Yong-Ping Chen
Journal:  BMC Med       Date:  2022-06-27       Impact factor: 11.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.